Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide is a synthetic small molecule belonging to the benzenesulfonamide class. It was designed as a potent and selective inhibitor of human carbonic anhydrase II (CA II), an enzyme involved in the reversible hydration of carbon dioxide. The compound exhibits picomolar affinity for CA II, with the R-enantiomer showing higher potency than its S-enantiomer. Its mechanism involves binding to and inhibiting the catalytic activity of CA II, which plays roles in pH regulation and CO₂ transport. This compound has been studied primarily as a chemical probe or lead structure for drug discovery rather than as a marketed pharmaceutical agent[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide.